KLOW Blend Protocol, Dosing & Timeline

KLOW Blend Overview

Mechanism of Action

KLOW Blend combines four peptides: GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg). KPV inhibits NF-κB to reduce inflammation, GHK-Cu promotes tissue remodeling, BPC-157 provides cytoprotection and angiogenesis, and TB-500 enables cell migration and repair. KPV's addition to the GLOW formula creates enhanced anti-inflammatory and immune-modulating activity.

Half-Life

Components have varying half-lives; combined effects persist hours

Timing

No specific timing required

Injection Site

Subcutaneous, abdomen

Food

No restrictions

Common Stacks

Standalone comprehensive blend
NAD+ — Cellular support

KLOW Blend Dosing Protocol

Standard Protocol

8–12 weeks

0.1–0.3 mL SQ daily

Blend dosed by volume.

Anti-inflammatory Focus

4–8 weeks

0.2–0.3 mL SQ daily

Higher dose for active inflammatory conditions.

KLOW Blend Expected Timeline

Week 1–2

Reduced inflammation; improved tissue comfort

Week 3–4

Enhanced wound healing and skin quality

Week 6–8

Sustained anti-inflammatory and regenerative effects

KLOW Blend Side Effects

Injection site irritation

Very well tolerated overall

KLOW Blend Research Studies

KPV exerts anti-inflammatory properties

Dalmasso G, et al. — Proc Natl Acad Sci USA (2008)

Demonstrated KPV's potent NF-κB inhibition and anti-inflammatory effects, the key addition differentiating KLOW from GLOW.

PubMed: 18824688

KLOW Blend FAQ

How is KLOW different from GLOW?

KLOW adds KPV (Lysine-Proline-Valine), a potent anti-inflammatory tripeptide that inhibits NF-κB activation. KLOW is better suited for conditions with significant inflammatory component; GLOW focuses on regeneration and aesthetics.

Can KLOW help with gut inflammation?

Yes. Both KPV and BPC-157 have been studied for gut inflammation. KPV reduces intestinal inflammatory cytokines, BPC-157 promotes gut mucosal healing. The combination may provide synergistic benefits.